Abstract
Compared to the use of DPP4i, that of SGLT2i was associated with a lower risk of AF in patients with T2D. Our findings contribute to the real-world evidence regarding the effectiveness of SGLT2i in preventing AF and support a tailored therapeutic approach to optimize treatment selection based on individual characteristics.
Introduction
Type 2 diabetes (T2D) is a significant risk factor for atrial fibrillation (AF), primarily through structural and electrical "remodeling" of the heart's atria. This remodeling creates a substrate for AF, which in turn increases the risk of stroke and heart failure. While Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have established benefits in glycemic control and heart failure management, their role in preventing the onset of AF remains a subject of clinical debate. This study, published in Frontiers in Pharmacology, provides large-scale, real-world evidence from the U.S. Medicare population to clarify this relationship.
Methods and Data Selection
The researchers conducted a retrospective cohort study using a 15% random sample of Medicare fee-for-service claims data from 2017 to 2018. This database covers approximately 98% of the U.S. population aged 65 and older.
To minimize bias, the study employed Inverse Probability Treatment Weighting (IPTW) based on propensity scores. This balanced 52 baseline variables—including demographics, over 20 comorbidities (such as hypertension), and co-medications—between the SGLT2i group and a dipeptidyl peptidase-4 inhibitor (DPP4i) group. DPP4i served as an active comparator, as it is used for the same indication but has a neutral effect on cardiovascular outcomes.
The initial pool of approximately 268,000 individuals was refined to a final cohort of 97,436 eligible individuals (after IPTW adjustments and exclusions for pre-existing AF or Type 1 diabetes). The median follow-up period was 361 days.
Key Results
The analysis revealed a significant reduction in AF risk associated with SGLT2i use:
- Hazard Ratio (HR): 0.73 (95% CI: 0.57–0.91; p = 0.01), indicating a 27% lower risk of incident AF compared to DPP4i users.
- Incidence Rates: The adjusted incidence rate was 8.39 per 1,000 person-years for the SGLT2i group, compared to 11.70 for the DPP4i group.
- Subgroup Analysis: The protective effect was most robust in patients with pre-existing Atherosclerotic Cardiovascular Disease (ASCVD) (HR 0.77) and Chronic Kidney Disease (CKD) (HR 0.70).
Discussion
The findings suggest that SGLT2i drugs offer "upstream" cardioprotective benefits beyond simple glucose lowering. Mechanistically, preclinical data suggests these drugs may inhibit sodium-hydrogen exchange in cardiac cells, thereby reducing cellular stress and subsequent atrial remodeling.
Limitations
As a claims-based study, there are inherent limitations:
- Missing Clinical Data: Metrics such as BMI, smoking status, and HbA1c levels were unavailable.
- Coding Accuracy: The study relies on the accuracy of ICD-10 coding for AF diagnosis.
- Follow-up Duration: The median follow-up of less than one year captures short-to-medium-term effects but does not address long-term outcomes.
Conclusion
In older adults with T2D, SGLT2i use is associated with a significantly lower risk of new-onset atrial fibrillation compared to DPP4i. These results support a tailored therapeutic approach, particularly for patients with existing cardiovascular or renal comorbidities who may derive the greatest benefit from SGLT2i therapy. Future research should investigate whether these findings represent a class-wide effect or vary between specific SGLT2i agents.
Summary updated